For the first time in half a century, the federal government has moved marijuana off Schedule I - placing state-licensed medical cannabis under Schedule III of the Controlled Substances Act through a final order from the acting attorney general. The rescheduling is partial and conditional, applying specifically to state-licensed medical marijuana operations, not to recreational markets or unregistered activity. For operators who qualify, the implications are immediate and significant - but only if they do the work required to claim them.
What Actually Changed, and What It Means for Operators
The two most consequential changes arrive together. First, state-licensed medical cannabis operators are no longer subject to Internal Revenue Code Section 280E - the provision that, for decades, barred cannabis businesses from deducting ordinary and necessary business expenses because they were trafficking in a Schedule I or II controlled substance. Running a cannabis dispensary under 280E meant paying federal income tax on gross profit rather than net income. That structural disadvantage disappears going forward, and the order encourages the Treasury Department to consider retroactive relief, though it stops short of making that determination itself. Operators should contact qualified tax counsel immediately - the potential exposure and opportunity here are both substantial.
Second, the banking problem gets materially easier. Financial institutions have long avoided cannabis clients because federal law treated the business as drug trafficking, exposing banks to money laundering liability. Rescheduling doesn't eliminate every compliance concern overnight, but it removes the Schedule I predicate that made serving cannabis businesses so legally fraught. Access to conventional banking, credit, and institutional capital should improve - not instantaneously, but meaningfully, and sooner than most operators have dared to plan for.
The Registration Requirement Is Not Optional
Here's the catch: none of these benefits are automatic. To operate lawfully under the new federal framework, state-licensed medical cannabis manufacturers, distributors, and dispensers must register with the Drug Enforcement Administration. The process requires submitting the applicable DEA forms alongside proof of a current state medical marijuana license. That state license functions as conclusive evidence of state-law authorization - DEA must grant registration unless doing so would conflict with the public interest or relevant international treaty obligations, most notably the Single Convention on Narcotic Drugs of 1961.
The 60-day window matters. Operators who apply within 60 days of the order's publication can continue operating under their state license while DEA processes their application - a process the agency is directed to complete within six months. Miss that window and the interim operating protection may not apply. Apply promptly.
Registration also defines the outer limit of what a licensee may do. Manufacturers can cultivate, produce, process, package, label, and transfer product to registered distributors or other manufacturers. Distributors receive from manufacturers and transfer to dispensers or other distributors. Dispensers dispense to individuals authorized under state law. These lanes are fixed; no registration authorizes non-medical purposes.
Operational Requirements: More Manageable Than They Sound
The final order appears to have been drafted with operational burden in mind - at least for the record-keeping and compliance requirements. State-required records are accepted to the maximum extent permissible under federal law, and DEA reporting is limited to what is actually necessary to satisfy statutory and treaty obligations. State-law requirements govern labeling, packaging, disposal, and physical security in lieu of federal defaults, with one addition: labels must include the statutory warning under 21 U.S.C. § 825(c), which notifies patients that transferring the drug to any person other than the patient is a federal crime.
State-authorized certifications - including electronic ones - are sufficient for dispensing, provided they include the patient's name and address, are dated and signed on the day of issuance, and identify the issuing practitioner by state license number. Practitioners do not need DEA prescriber registration under the new framework.
One requirement is genuinely unusual, and operators should understand it clearly. Because of U.S. obligations under the Single Convention - which requires that a government entity hold title to narcotic crops - manufacturers must establish a nominal price for their marijuana crops. DEA then purchases those crops at that nominal price and sells them back to the manufacturer, or a related entity, at the same price plus an administrative fee. Cultivation must occur in areas specified in the DEA registration, and crops must be stored in a facility to which DEA maintains access until the transaction is complete. The economics are essentially a pass-through; the legal architecture is there to satisfy treaty obligations rather than to extract value from operators.
Keeping Your Federal Authorization Means Keeping Your State License
Federal authorization tracks state authorization, full stop. If a state license is suspended, revoked, or simply expires, DEA registration suspends automatically. This is not a technicality - it is the load-bearing structure of the entire framework. Operators who have let state compliance slide, or who are approaching renewal without attention to it, face federal consequences they didn't previously have to worry about. Maintaining good standing with state regulators is now a federal compliance obligation as well.
To put it plainly: this is the most significant shift in federal marijuana policy in the modern era. The 280E relief alone could transform the economics of state-licensed medical cannabis operations. But the order grants no grace for operators who assume the benefits flow automatically. Register with DEA within 60 days. Audit your state license status. Get qualified tax counsel on the 280E question - both prospective and retroactive. The framework is workable. The window is open. Use it.
